Enhancement of the immunoregulatory potency of mesenchymal stromal cells by treatment with immunosuppressive drugs

The use of treated MSCs may achieve clinical end points not reached with untreated MSCs and allow for infusion of fewer cells to reduce costs and minimize potential side effects.